Research ExplorerPublicationsFäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-...

Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers

Standard

Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers. / Hagel, Stefan; Fischer, Anne; Ehlermann, Philipp; Frank, Thorsten; Tueffers, Kester; Sturm, Andreas; Link, Alexander; Demir, Muenevver; Siebenhaar, Arno; Storr, Martin; Glueck, Thomas; Siegel, Erhard; Solbach, Philip; Goeser, Felix; Koelbel, Christian B.; Lohse, Ansgar; Luebbert, Christoph; Kandzi, Ulrich; Maier, Matthias; Schuerle, Stefanie; Lerch, Markus M.; Tacke, Daniela; Cornely, Oliver A.; Stallmach, Andreas; Vehreschild, Maria; German Clinical Microbiome Study Group (GCMSG), on behalf of the .

In: DTSCH ARZTEBL INT, Vol. 113, No. 35-36, 05.09.2016, p. 583-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hagel, S, Fischer, A, Ehlermann, P, Frank, T, Tueffers, K, Sturm, A, Link, A, Demir, M, Siebenhaar, A, Storr, M, Glueck, T, Siegel, E, Solbach, P, Goeser, F, Koelbel, CB, Lohse, A, Luebbert, C, Kandzi, U, Maier, M, Schuerle, S, Lerch, MM, Tacke, D, Cornely, OA, Stallmach, A, Vehreschild, M & German Clinical Microbiome Study Group (GCMSG), OBOT 2016, 'Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers', DTSCH ARZTEBL INT, vol. 113, no. 35-36, pp. 583-9. https://doi.org/10.3238/arztebl.2016.0583

APA

Hagel, S., Fischer, A., Ehlermann, P., Frank, T., Tueffers, K., Sturm, A., Link, A., Demir, M., Siebenhaar, A., Storr, M., Glueck, T., Siegel, E., Solbach, P., Goeser, F., Koelbel, C. B., Lohse, A., Luebbert, C., Kandzi, U., Maier, M., ... German Clinical Microbiome Study Group (GCMSG), O. B. O. T. (2016). Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers. DTSCH ARZTEBL INT, 113(35-36), 583-9. https://doi.org/10.3238/arztebl.2016.0583

Vancouver

Hagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A et al. Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers. DTSCH ARZTEBL INT. 2016 Sep 5;113(35-36):583-9. https://doi.org/10.3238/arztebl.2016.0583

Bibtex

@article{407b75c7c3854c93ac0cfbafad8d9789,
title = "F{\"a}kaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers",
abstract = "BACKGROUND: The clinical effectiveness of fecal microbiota transplant (FMT) for the treatment of recurrent Clostridium difficile infections (rCDI) has been demonstrated in randomized controlled trials. To assess the current status of FMT in Germany with respect to active centers, local standards, clinical effectiveness and safety, the MicroTrans Registry (NCT02681068) was established.METHODS: In a long-term retrospective multicenter observational study by the German Clinical Microbiome Study Group (GCMSG), primary and secondary cure on day 30 and 90, as well as occurrence of treatment-related adverse events were assessed. In addition to patient demographic data, we provide an overview of the FMT procedures and techniques used at different centers.RESULTS: Overall, 133 eligible patients from 33 centers were included, of which 64.7% were female (n = 86). The mean age was 75 years (interquartile range: 59.5-81.5). Administration via the duodenal route (n = 59; 44.4%) was the most frequently applied option, followed by colonic (n = 55; 41.1%), capsule (n = 13; 9.8%), and gastric administration (n = 4; 3.0%). Primary cure on day 30 and 90 was achieved in 84.2% (n = 101/120) and 78.3% (n = 72/92) of patients, respectively. Including re-treatment, secondary response was achieved in 87.5% (d 30; n = 105/120) and 85.9% (d 90; n = 79/92), respectively. Treatment- elated adverse events were documented in 16 patients (12.0%).CONCLUSION: FMT is a safe and effective treatment option for rCDI. However, FMT is currently available only in few centers in Germany, and treatment options vary from one center to another.",
keywords = "Journal Article",
author = "Stefan Hagel and Anne Fischer and Philipp Ehlermann and Thorsten Frank and Kester Tueffers and Andreas Sturm and Alexander Link and Muenevver Demir and Arno Siebenhaar and Martin Storr and Thomas Glueck and Erhard Siegel and Philip Solbach and Felix Goeser and Koelbel, {Christian B.} and Ansgar Lohse and Christoph Luebbert and Ulrich Kandzi and Matthias Maier and Stefanie Schuerle and Lerch, {Markus M.} and Daniela Tacke and Cornely, {Oliver A.} and Andreas Stallmach and Maria Vehreschild and {German Clinical Microbiome Study Group (GCMSG)}, {on behalf of the}",
year = "2016",
month = sep,
day = "5",
doi = "10.3238/arztebl.2016.0583",
language = "Deutsch",
volume = "113",
pages = "583--9",
journal = "DTSCH ARZTEBL INT",
issn = "1866-0452",
publisher = "Deutscher Arzte-Verlag",
number = "35-36",

}

RIS

TY - JOUR

T1 - Fäkaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers

AU - Hagel, Stefan

AU - Fischer, Anne

AU - Ehlermann, Philipp

AU - Frank, Thorsten

AU - Tueffers, Kester

AU - Sturm, Andreas

AU - Link, Alexander

AU - Demir, Muenevver

AU - Siebenhaar, Arno

AU - Storr, Martin

AU - Glueck, Thomas

AU - Siegel, Erhard

AU - Solbach, Philip

AU - Goeser, Felix

AU - Koelbel, Christian B.

AU - Lohse, Ansgar

AU - Luebbert, Christoph

AU - Kandzi, Ulrich

AU - Maier, Matthias

AU - Schuerle, Stefanie

AU - Lerch, Markus M.

AU - Tacke, Daniela

AU - Cornely, Oliver A.

AU - Stallmach, Andreas

AU - Vehreschild, Maria

AU - German Clinical Microbiome Study Group (GCMSG), on behalf of the

PY - 2016/9/5

Y1 - 2016/9/5

N2 - BACKGROUND: The clinical effectiveness of fecal microbiota transplant (FMT) for the treatment of recurrent Clostridium difficile infections (rCDI) has been demonstrated in randomized controlled trials. To assess the current status of FMT in Germany with respect to active centers, local standards, clinical effectiveness and safety, the MicroTrans Registry (NCT02681068) was established.METHODS: In a long-term retrospective multicenter observational study by the German Clinical Microbiome Study Group (GCMSG), primary and secondary cure on day 30 and 90, as well as occurrence of treatment-related adverse events were assessed. In addition to patient demographic data, we provide an overview of the FMT procedures and techniques used at different centers.RESULTS: Overall, 133 eligible patients from 33 centers were included, of which 64.7% were female (n = 86). The mean age was 75 years (interquartile range: 59.5-81.5). Administration via the duodenal route (n = 59; 44.4%) was the most frequently applied option, followed by colonic (n = 55; 41.1%), capsule (n = 13; 9.8%), and gastric administration (n = 4; 3.0%). Primary cure on day 30 and 90 was achieved in 84.2% (n = 101/120) and 78.3% (n = 72/92) of patients, respectively. Including re-treatment, secondary response was achieved in 87.5% (d 30; n = 105/120) and 85.9% (d 90; n = 79/92), respectively. Treatment- elated adverse events were documented in 16 patients (12.0%).CONCLUSION: FMT is a safe and effective treatment option for rCDI. However, FMT is currently available only in few centers in Germany, and treatment options vary from one center to another.

AB - BACKGROUND: The clinical effectiveness of fecal microbiota transplant (FMT) for the treatment of recurrent Clostridium difficile infections (rCDI) has been demonstrated in randomized controlled trials. To assess the current status of FMT in Germany with respect to active centers, local standards, clinical effectiveness and safety, the MicroTrans Registry (NCT02681068) was established.METHODS: In a long-term retrospective multicenter observational study by the German Clinical Microbiome Study Group (GCMSG), primary and secondary cure on day 30 and 90, as well as occurrence of treatment-related adverse events were assessed. In addition to patient demographic data, we provide an overview of the FMT procedures and techniques used at different centers.RESULTS: Overall, 133 eligible patients from 33 centers were included, of which 64.7% were female (n = 86). The mean age was 75 years (interquartile range: 59.5-81.5). Administration via the duodenal route (n = 59; 44.4%) was the most frequently applied option, followed by colonic (n = 55; 41.1%), capsule (n = 13; 9.8%), and gastric administration (n = 4; 3.0%). Primary cure on day 30 and 90 was achieved in 84.2% (n = 101/120) and 78.3% (n = 72/92) of patients, respectively. Including re-treatment, secondary response was achieved in 87.5% (d 30; n = 105/120) and 85.9% (d 90; n = 79/92), respectively. Treatment- elated adverse events were documented in 16 patients (12.0%).CONCLUSION: FMT is a safe and effective treatment option for rCDI. However, FMT is currently available only in few centers in Germany, and treatment options vary from one center to another.

KW - Journal Article

U2 - 10.3238/arztebl.2016.0583

DO - 10.3238/arztebl.2016.0583

M3 - SCORING: Zeitschriftenaufsatz

C2 - 27658471

VL - 113

SP - 583

EP - 589

JO - DTSCH ARZTEBL INT

JF - DTSCH ARZTEBL INT

SN - 1866-0452

IS - 35-36

ER -